The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

UBT251 is different from Novo Nordisk’s current drugs like Ozempic and Wegovy. The drug combines GLP-1 and GIP, which lower appetite and blood sugar, with glucagon, which helps prevent ...

Novo Nordisk (NYSE:NVO)) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to supercharge its manufacturing plant in Montes Claros.

SAO PAULO (Reuters) - Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost production, it said on Monday. The ...

HYDERABAD (Reuters) - Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster ... Semaglutide, the active ingredient in Novo's Wegovy and diabetes medicine Ozempic, goes off ...

into enzyme production for semaglutide-based drugs like Ozempic and Wegovy. The company's decision underscores Brazil's strategic importance within its global operations. Novo Nordisk Expands in ...

SAO PAULO, April 7 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost ...

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S NVO, reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for 2024.

Eli Lilly’s weight-loss drugs, Zepbound and Mounjaro, directly rival Novo Nordisk’s Wegovy and Ozempic, intensifying the competitive landscape. Year-to-date, Novo’s shares have dropped 25%, while ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory. Investors ...

Ozempic improved maximum walking distance by 13% in peripheral artery disease patients over 52 weeks. Rybelsus reduced the risk of major cardiovascular events by 14% in high-risk patients.